The significant therapeutic effect against this tumour suggests that antibody-mediated inhibition of BTNL2 may hold promise in combination with anti-PD-1/PD-L1 ICBs, and furthermore, may open the door to immunotherapy for tumours that have previously been considered “cold”. Here, CD274 is linked to neoplasm.